Evidence map›Paper›PMID 42262889›Full record

ArticleJournal of medicinal chemistry2026

Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation.

Anshul Mishra, Wen-Bin Yang, Tsu-Shao Liu, Amandeep Thakur, Ajmer Singh Grewal, Jacek Marczyk, Giovanni Stelitano, Ram Sharma, Mandeep Rana, Gurpreet Singh and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anshul MishraSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Wen-Bin YangResearch Center for Neuroscience, Taipei Medical University, Taipei 110031, Taiwan.ORCID 0000-0002-6497-4176
Tsu-Shao LiuSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Amandeep ThakurSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Ajmer Singh GrewalDepartment of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Near Guru Nanak Khalsa College, Yamuna Nagar 135001, Haryana, India.ORCID 0000-0002-2418-9616
Jacek MarczykOntonix S.r.l, 23100 Sondrio, Italy.
Giovanni StelitanoDepartment of Biotechnology, University of Pavia, Via Ferrata 9, 27100 Pavia, Italy.
Ram SharmaSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Mandeep RanaSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Gurpreet SinghDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142001, Punjab, India.ORCID 0000-0002-1421-3782
Santosh Kumar GuruDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India.
Goutam RathDepartment of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar 751003, Odisha, India.
Saurabh ChawlaSchool of Biological Sciences, National Institute of Science Education and Research (NISER), P.O. Bhimpur-Padanpur, Jatni, Khurda, Bhubaneswar 752050, Odisha, India.
Jing Ping LiouSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.ORCID 0000-0002-3775-6405
Chun Hsu PanSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.ORCID 0000-0001-8700-583X
Kunal NepaliSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.ORCID 0000-0002-6443-7928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An integrated transcriptomic and survival analysis led to the identification of SYK and HDAC isoforms as age- and FLT3-dependent prognostic markers in acute myeloid leukemia (AML). Driven by the aforementioned, our research group employed a classical ligand-based hybrid pharmacophore strategy to furnish dual-target hybrid frameworks. Antitumor profiling culminated in a tractable bifunctional agent (Compound

Indexed as

Antineoplastic AgentsDrug DesignHistone Deacetylase InhibitorsLeukemia, Myeloid, AcuteProtein Kinase InhibitorsSyk KinaseAnimalsCell Line, TumorCell ProliferationFemaleHistone DeacetylasesHumansMiceStructure-Activity RelationshipTyrosine Kinase InhibitorsXenograft Model Antitumor AssaysAntineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesProtein Kinase InhibitorsSyk KinaseSYK protein, humanTyrosine Kinase Inhibitors

Identifiers

PMID42262889
PMCPMC13312455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.